Gastrointestinal endoscopy · 2015
Survival and clinical outcome after endoscopic duodenal stent placement for malignant gastric outlet obstruction: comparison of pancreatic cancer and nonpancreatic cancer.
Clinical StudyСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oh Stephen Y, Edwards Alicia, Mandelson Margaret, Ross Andrew, Irani Shayan, Larsen Michael, Gan Seng-Ian, Gluck Michael, Picozzi Vincent, Helton Scott, Kozarek Richard A
Аннотация
BACKGROUND: Data on endoscopic stenting of malignant gastric outlet obstruction (GOO) are based on studies predominantly involving patients with pancreatic adenocarcinoma.
OBJECTIVE: To compare survival and clinical outcome after stent placement for GOO due to pancreatic cancer compared with nonpancreatic cancer.
DESIGN: Retrospective study.
SETTING: Single tertiary hospital.
PATIENTS: A total of 292 patients with malignant GOO.
INTERVENTION: Stent placement.
MAIN OUTCOME MEASUREMENTS: Post-stent placement survival and clinical outcome.
RESULTS: In 196 patients with pancreatic cancer and 96 with nonpancreatic cancer, median post-stent placement survival was similar (2.7 months in pancreatic cancer vs 2.4 months in nonpancreatic cancer). Overall survival was shorter in patients with pancreatic cancer (13.7 vs 17.1 months; P = .004). Clinical success rates at 2 months (71% vs 91%) and reintervention rates (30% vs 23%) were comparable. Post-stent placement chemotherapy and the absence of distant metastasis were associated with better post-stent placement survival in both groups (pancreatic cancer: chemotherapy vs no chemotherapy, 5.4 vs 1.5 months, P < .0001; metastasis vs no metastasis, 1.8 vs 4.6, P = .005; nonpancreatic cancer: chemotherapy vs no chemotherapy, 9.2 vs 1.8, P = .001; metastasis vs no metastasis, 2.1 vs 6.1, P = .009).
LIMITATIONS: Retrospective study.
CONCLUSIONS: In this large series of patients undergoing stent placement for malignant GOO in North America, we observed no difference in post-stent placement survival despite better overall survival in patients with nonpancreatic cancer. GOO is a marker for poor survival in malignancy, regardless of the type. Chemotherapy and the absence of distant metastasis were associated with better post-stent placement survival in both groups.
OBJECTIVE: To compare survival and clinical outcome after stent placement for GOO due to pancreatic cancer compared with nonpancreatic cancer.
DESIGN: Retrospective study.
SETTING: Single tertiary hospital.
PATIENTS: A total of 292 patients with malignant GOO.
INTERVENTION: Stent placement.
MAIN OUTCOME MEASUREMENTS: Post-stent placement survival and clinical outcome.
RESULTS: In 196 patients with pancreatic cancer and 96 with nonpancreatic cancer, median post-stent placement survival was similar (2.7 months in pancreatic cancer vs 2.4 months in nonpancreatic cancer). Overall survival was shorter in patients with pancreatic cancer (13.7 vs 17.1 months; P = .004). Clinical success rates at 2 months (71% vs 91%) and reintervention rates (30% vs 23%) were comparable. Post-stent placement chemotherapy and the absence of distant metastasis were associated with better post-stent placement survival in both groups (pancreatic cancer: chemotherapy vs no chemotherapy, 5.4 vs 1.5 months, P < .0001; metastasis vs no metastasis, 1.8 vs 4.6, P = .005; nonpancreatic cancer: chemotherapy vs no chemotherapy, 9.2 vs 1.8, P = .001; metastasis vs no metastasis, 2.1 vs 6.1, P = .009).
LIMITATIONS: Retrospective study.
CONCLUSIONS: In this large series of patients undergoing stent placement for malignant GOO in North America, we observed no difference in post-stent placement survival despite better overall survival in patients with nonpancreatic cancer. GOO is a marker for poor survival in malignancy, regardless of the type. Chemotherapy and the absence of distant metastasis were associated with better post-stent placement survival in both groups.
Предметные рубрики MeSH
AdenocarcinomaAgedAmpulla of VaterAntineoplastic AgentsBile Duct NeoplasmsCholangiocarcinomaCohort StudiesCommon Bile Duct NeoplasmsDuodenal NeoplasmsDuodenumEndoscopy, Digestive SystemFemaleGastric Outlet ObstructionHumansMaleMiddle AgedPancreatic NeoplasmsRetrospective StudiesStentsStomach NeoplasmsSurvival RateTreatment Outcome